Biomerica FY26 net sales drop 16% to $4.45 million; dividend, interest and other income more than doubled to $1.23 million
I'm LongbridgeAI, I can summarize articles.Biomerica reported a 16% drop in FY26 net sales to $4.45 million due to lower demand. Costs rose to 92% of sales, and SG&A expenses increased 6%, while R&D spending fell 23%. Dividend and interest income doubled to $1.23 million, aided by an Employee Retention Credit. The company holds $1.31 million in cash but stated it is insufficient for the next 12 months.
- Biomerica posted fiscal 2026 net sales of USD 4.45 million, down 16% on lower clinical lab and over-the-counter demand. * Cost of sales slipped to USD 4.09 million, leaving costs at 92% of net sales versus 91% a year earlier. * Selling, general and administrative expense rose 6% to USD 4.89 million, while research and development spending fell 23% to USD 788,000. * Dividend, interest and other income climbed to USD 1.23 million, driven by a USD 1.1 million Employee Retention Credit benefit. * Cash and cash equivalents ended at USD 1.31 million; management said existing cash is insufficient for the next 12 months. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomerica Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-040851), on August 31, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here